Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Partnership Supports Mydecine’s Drug Development & Clinical Trials Pipeline Provides Update on Debt Settlement *NOT FOR DISTRIBUTION…

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA)…

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA)…

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or…

Mydecine Innovations Group Files Application to list to the NASDAQ

DENVER, Jan. 27, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA)…

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA…

Mydecine Innovations Group Shares Intellectual Property Update

Company files seven provisional patent applications with United States Patent and Trademark Office DENVER, Jan. 07,…

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or…